TQ Pharma held its first scientific forum in cooperation with the Association of Vascular Surgeons at the Kempinski Hotel – Dead Sea, with the aim of discussing the latest studies and scientific developments related to the treatment of deep vein thrombosis (DVT).

During the forum, TQ Pharma also introduced its product XAVIR, containing the active ingredient Rivaroxaban, available in a range of strengths. The product has been launched in both the local market and export markets, contributing to expanding modern treatment options for deep vein thrombosis (DVT).

We extend our sincere thanks to all the physicians who attended the forum for their valuable participation, meaningful interaction, and contribution to enriching the scientific discussion and reviewing the latest developments in the field of vascular surgery.

The forum was organized as part of TQ Pharma’s ongoing commitment to strengthening scientific communication and the exchange of expertise, supporting continuing medical education, and contributing to the advancement of the healthcare sector.